Bioventix (BVXP) - Net Assets

Latest as of December 2025: GBX11.04 Million GBX ≈ $1.34K USD

Based on the latest financial reports, Bioventix (BVXP) has net assets worth GBX11.04 Million GBX (≈ $1.34K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX13.03 Million ≈ $1.59K USD) and total liabilities (GBX1.99 Million ≈ $242.48 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Bioventix debt and liabilities for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	GBX11.04 Million
% of Total Assets	84.71%
Annual Growth Rate	N/A
5-Year Change	-2.27%
10-Year Change	40.75%
Growth Volatility	76.87

Bioventix - Net Assets Trend (2006–2025)

This chart illustrates how Bioventix's net assets have evolved over time, based on quarterly financial data. Also explore BVXP total asset value for the complete picture of this company's asset base.

Annual Net Assets for Bioventix (2006–2025)

The table below shows the annual net assets of Bioventix from 2006 to 2025. For live valuation and market cap data, see market cap of Bioventix.

Year	Net Assets	Change
2025-06-30	GBX11.55 Million ≈ $1.41K	-3.76%
2024-06-30	GBX12.00 Million ≈ $1.46K	-0.51%
2023-06-30	GBX12.06 Million ≈ $1.47K	+2.05%
2022-06-30	GBX11.82 Million ≈ $1.44K	+0.01%
2021-06-30	GBX11.82 Million ≈ $1.44K	-5.60%
2020-06-30	GBX12.52 Million ≈ $1.52K	+15.65%
2019-06-30	GBX10.83 Million ≈ $1.32K	-1.68%
2018-06-30	GBX11.01 Million ≈ $1.34K	+8.54%
2017-06-30	GBX10.14 Million ≈ $1.23K	+23.60%
2016-06-30	GBX8.21 Million ≈ $998.60	+24.65%
2015-06-30	GBX6.58 Million ≈ $801.10	+25.74%
2014-06-30	GBX5.24 Million ≈ $637.09	+24.53%
2013-06-30	GBX4.20 Million ≈ $511.61	+25.90%
2012-06-30	GBX3.34 Million ≈ $406.34	+24.74%
2011-06-30	GBX2.68 Million ≈ $325.76	+13.16%
2010-06-30	GBX2.37 Million ≈ $287.87	+178.03%
2009-06-30	GBX851.00K ≈ $103.54	+299.53%
2008-06-30	GBX213.00K ≈ $25.92	+244.90%
2007-06-30	GBX-147.00K ≈ $-17.89	-107.04%
2006-06-30	GBX-71.00K ≈ $-8.64	--

Equity Component Analysis

This analysis shows how different components contribute to Bioventix's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 16421.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Retained Earnings	GBX9.75 Million	84.39%
Common Stock	GBX261.24K	2.26%
Other Comprehensive Income	GBX1.23K	0.01%
Other Components	GBX1.54 Million	13.34%
Total Equity	GBX11.55 Million	100.00%

Bioventix Competitors by Market Cap

The table below lists competitors of Bioventix ranked by their market capitalization.

Company	Market Cap
Anpario Plc LSE:ANP	$1.10 Million
Lithium One Metals Inc V:LONE	$1.10 Million
SIG plc LSE:SHI	$1.10 Million
MTI Investment SE ST:MTI	$1.10 Million
Lifeist Wellness Inc V:LFST	$1.10 Million
Metavisio (Thomson Computing) PA:ALTHO	$1.10 Million
Tres Or Resources Ltd V:TRS	$1.10 Million
Hub Cyber Security Ltd. Ordinary Shares NASDAQ:HUBC	$1.09 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bioventix's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 12,002,658 to 11,551,717, a change of -450,941 (-3.8%).
Net income of 7,584,442 contributed positively to equity growth.
Dividend payments of 8,194,860 reduced retained earnings.
New share issuances of 70,254 increased equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	GBX7.58 Million	+65.66%
Dividends Paid	GBX8.19 Million	-70.94%
Share Issuances	GBX70.25K	+0.61%
Other Changes	GBX89.22K	+0.77%
Total Change	GBX-	-3.76%

Book Value vs Market Value Analysis

This analysis compares Bioventix's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 790.38x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 3238.09x to 790.38x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-06-30	GBX0.53	GBX1725.00	x
2012-06-30	GBX0.66	GBX1725.00	x
2013-06-30	GBX0.84	GBX1725.00	x
2014-06-30	GBX1.02	GBX1725.00	x
2015-06-30	GBX1.28	GBX1725.00	x
2016-06-30	GBX1.60	GBX1725.00	x
2017-06-30	GBX1.95	GBX1725.00	x
2018-06-30	GBX2.11	GBX1725.00	x
2019-06-30	GBX2.07	GBX1725.00	x
2020-06-30	GBX2.40	GBX1725.00	x
2021-06-30	GBX2.25	GBX1725.00	x
2022-06-30	GBX2.25	GBX1725.00	x
2023-06-30	GBX2.28	GBX1725.00	x
2024-06-30	GBX2.27	GBX1725.00	x
2025-06-30	GBX2.18	GBX1725.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bioventix utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 65.66%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 57.83%
• Asset Turnover: 1.02x
• Equity Multiplier: 1.11x
Recent ROE (65.66%) is above the historical average (50.56%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	33.03%	44.82%	0.69x	1.07x	GBX616.72K
2012	37.05%	51.90%	0.67x	1.06x	GBX903.23K
2013	36.18%	56.22%	0.60x	1.07x	GBX1.10 Million
2014	34.67%	51.35%	0.61x	1.10x	GBX1.29 Million
2015	38.84%	59.02%	0.63x	1.05x	GBX1.90 Million
2016	42.58%	63.34%	0.63x	1.07x	GBX2.67 Million
2017	48.52%	67.93%	0.70x	1.02x	GBX3.91 Million
2018	51.43%	64.71%	0.74x	1.08x	GBX4.56 Million
2019	54.14%	63.10%	0.80x	1.07x	GBX4.78 Million
2020	57.53%	69.84%	0.78x	1.06x	GBX5.95 Million
2021	56.95%	61.58%	0.85x	1.09x	GBX5.55 Million
2022	64.92%	65.48%	0.89x	1.11x	GBX6.49 Million
2023	69.40%	65.33%	0.96x	1.10x	GBX7.17 Million
2024	67.46%	59.51%	0.99x	1.14x	GBX6.90 Million
2025	65.66%	57.83%	1.02x	1.11x	GBX6.43 Million

Industry Comparison

This section compares Bioventix's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $8,626,280
Average return on equity (ROE) among peers: -285.67%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Bioventix (BVXP)	GBX11.04 Million	33.03%	0.18x	$1.10 Million
4BASEBIO UK SOCIETAS (4BB)	$7.12 Million	-72.33%	0.64x	$951.45K
Aptamer Group PLC (APTA)	$245.81K	-274.50%	4.65x	$205.09K
Arecor Therapeutics PLC (AREC)	$5.35 Million	-191.36%	0.63x	$303.20K
Avacta Group PLC (AVCT)	$29.89 Million	-21.30%	0.06x	$3.99 Million
BSF Enterprise Plc (BSFA)	$3.58 Million	-25.96%	0.13x	$27.33K
Cizzle Biotechnology Holdings PLC (CIZ)	$32.00K	-956.25%	1.81x	$127.81K
Amur Minerals Corporation (CRTX)	$20.48 Million	-8.91%	0.04x	$80.26K
Fusion Antibodies PLC (FAB)	$50.13K	-935.06%	5.06x	$193.60K
Faron Pharmaceuticals Oy (FARN)	$10.88 Million	-85.40%	0.59x	$575.13K

About Bioventix

LSE:BVXP UK Biotechnology

Market Cap

$1.10 Million

GBX9.01 Billion GBX

Market Cap Rank

#30150 Global

#785 in UK

Share Price

GBX1725.00

Change (1 day)

+0.00%

52-Week Range

GBX1375.00 - GBX3020.00

All Time High

GBX4868.77